OncoTargets and Therapy (Dec 2021)
CBX7, a Potential Prognostic Biomarker in Lung Adenocarcinoma
Abstract
Yanlong Yang,1,* Zaoxiu Hu,2,* Hongwen Sun,1 Qinghe Yu,1 Linzhu Yang,1 Fang Yin,1 Yongmen Sun,1 Lisha Pu,3 Xingming Zhu,1 Shen Li,4 Xiaobo Chen,1 Yunping Zhao1 1Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, People’s Republic of China; 2Department of Pathology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, 650118, People’s Republic of China; 3Department of Nephrology, Kunming Yanan Hospital, Kunming, 650051, People’s Republic of China; 4Department of Thoracic Surgery, Baoshan People’s Hospital, Baoshan, 678000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiaobo Chen; Yunping ZhaoDepartment of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Wuhua District, Kunming, 650032, Yunnan Province, People’s Republic of ChinaTel/Fax +86 87165324888Email [email protected]; [email protected]: Lung adenocarcinoma (LUAD) is a major type of NSCLC and has high morbidity and mortality. The identification of useful prognostic biomarkers for LUAD is important. CBX7 has been reported in various cancers yet its expression level and potential roles have not been fully understood.Methods: GEPIA, Oncomine, TCGA, KM plotter and OSluca databases were used to explore the expression profile and prognostic effects of CBX7 mRNA expression in patients with LUAD. TIMER was used to explore the relationship between CBX7 and immune infiltrating cells. GSEA was used to further explore the potential biological process and pathways regulated by CBX7 in LUAD. Lastly, IHC detection of CBX7 in 95 samples was used to validate the result.Results: We found CBX7 was downregulated in LUAD in GEPIA, Oncomine and TCGA databases. TCGA, KM plotter and OSluca databases suggested that CBX7 was associated with poor clinical outcomes and low survival rate. Using TIMER, we found that CBX7 might be associated with immune infiltration. Via gene set enrichment analysis, we found that tumor-associated biological processes and signaling pathways were enriched in the CBX7 downregulated group. Using clinical samples, we found that CBX7 protein has low expression in LUAD and was associated with poor survival.Conclusion: CBX7 might serve as a promising biomarker and potential molecular target in LUAD.Keywords: CBX7, LUAD, prognosis, biomarker, immune infiltration
